Tag

Pre-Exposure Prophylaxis

Edge Media Names Policy Brief On PrEP For Transgender Women As One Of Top Women’s Health Stories Of 2016

By | Fenway Health Newsroom, HIV/AIDS, Trans | No Comments
Edge Media Network has highlighted policy brief “Transgender women and pre-exposure prophylaxis for HIV prevention: What we know and what we still need to know” as one of the most important women’s health stories of 2016. The brief was released last winter by the National Center for Innovation in HIV Care—a program of The Fenway Institute, AIDS United, and ARCW. In it, researchers explored the interaction between feminizing hormones used by transgender women, and the medication currently approved for use as pre-exposure prophylaxis for HIV prevention (PrEP). The brief also brought attention to the urgent need for more lifesaving research 
Read More

Ready for Vacation? New Study Puts the “PrEP” in “Travel Preparation”

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
It’s officially vacation season, and many people are off to seaside getaways and exciting new destinations. A vacation from work, however, shouldn’t mean a vacation from making smart decisions about your sexual health. According to a 2013 study of men who have sex with men (MSM), 25.6 % reported condomless anal sex with new male sex partners while vacationing, and 1 in 5 reported going on vacation with a main goal of finding new sexual partners. From Provincetown to Fire Island, from gay cruises to circuit parties, LGBT safe spaces have always been spaces for freedom and sexual expression. Taking 
Read More

Preventing HIV with One Pill a Day: Using PrEP in Clinical Practice

By | Education, Events, Fenway Health Newsroom, Fenway News, HIV/AIDS, The Fenway Institute | No Comments
The Fenway Institute and the National LGBT Health Education Center are excited to announce an upcoming educational conference for medical providers about the usage of on PrEP (pre-exposure prophylaxis) for HIV prevention. PrEP, also known by the brand name Truvada, is a once-daily HIV prevention pill with the potential to make a significant contribution to ending the HIV/AIDS epidemic. You are invited to attend a continuing education conference focused on teaching providers how to incorporate PrEP into their clinical practice. The conference is for any providers – including primary care or other relevant providers – who are interested in becoming 
Read More

Vacation Study Examines Efficacy of Short-Term PrEP Use

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
As the weather grows colder, many people are starting to plan their 2016 vacations. Among the TSA screenings and hotel ratings, there is one rarely discussed aspect of travel planning and safety: sexual health. Research has shown that many men who have sex with men (MSM) have periods of elevated HIV risk that often coincide with times away from home or vacations. The often casual and spontaneous nature of sexual encounters while traveling can result in unprotected sex and, in doing so, raise one’s risk of HIV infection. Pre-exposure prophylaxis (PrEP), a daily pill to prevent HIV infection, is a 
Read More

New Campaign Highlights Benefits Of Daily PrEP Use

By | AIDS Action Committee, Fenway Health Newsroom, HIV Prevention, HIV/AIDS | No Comments
The AIDS Action Committee is pleased to announce the launch of a new advertising campaign that aims to educate the public on the benefits of pre-exposure prophylaxis (PrEP) in the fight against HIV. Also commonly known by the brand name Truvada, PrEP is a daily pill that, when taken daily, has proven to be 99% effective in preventing HIV infection. The Talk PrEP campaign hopes to raise public awareness of PrEP’s efficacy and encourage people to start conversations with their friends, family, and doctors about this life-saving drug. Anyone who is HIV-negative, does not have degenerative kidney or liver disease 
Read More